Servier’s decision to exit a Parkinson’s disease pact has triggered belt tightening at French biotech Oncodesign Precision Medicine. The loss of a shot at a milestone prompted OPM to lay off ...

Five months after cutting support for BDTX-4933, the biotech has licensed the RAF inhibitor to Servier for $70 million upfront and up to $710 million in milestones. In October, Black Diamond ...

Servier is already in the process of transforming itself into a much bigger player in cancer, and has just tripled its sales objectives for the category. Fresh with a new brand identity, the ...

Servier is paying $1.8 billion upfront for the oncology assets, with the total value of the deal potentially rising to $2 billion if Agios’ key pipeline candidate vorasidenib – a dual ...

Black Diamond Therapeutics' strategic deal with Servier makes BDTX undervalued, with a $70M upfront payment and potential $710M in milestone payments and royalties. BDTX is trading below its net ...

The partnership underscores Servier's commitment to developing targeted therapies that address unmet medical needs in oncology Servier will develop and commercialize BDTX-4933, a Phase 1 asset ...